NEW YORK, Nov. 28, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Apogee Enterprises, Inc. (NASDAQGS: APOG)
Class Period: June 28, 2018 to September 17, 2018
Lead Plaintiff Deadline: January 4, 2019
The complaint alleges that during the class period Apogee Enterprises, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Apogee lacked the required labor force in place to ramp-up its production; (ii) Apogee was unable to hire, train and retain new employees; (iii) Apogee’s productivity and margins would be negatively impacted; and (iv) as a result of the foregoing, Defendants’ statements about the Company’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
Get additional information about the APOG lawsuit: http://www.kleinstocklaw.com/pslra-1/apogee-enterprises-inc-loss-submission-form?wire=3
Trevena, Inc. (NASDAQGS: TRVN)
Class Period: May 2, 2016 to October 9, 2018
Lead Plaintiff Deadline: December 10, 2018
Trevena, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (a) during its meetings with the FDA prior to the start of the Class Period, Trevena had been advised that the FDA did not agree with certain aspects of the design of the Phase III clinical trial of Olinvo, including the proposed dosing, the proposed primary endpoint and the proposed non-inferiority margin for comparing morphine to Olinvo; (b) unless Trevena demonstrated that Olinvo was at least equally effective to morphine in treating post-operative pain in the Phase III clinical trial, the FDA would be unwilling to consider any secondary benefits Olinvo might confer in terms of reduced opioid-related adverse effects ("ORAEs"); (c) the FDA disagreed with how the safety data was being compiled in the Phase II clinical trial; (d) because the FDA did not agree with major tenants of the design of the Phase III clinical trial, it was highly unlikely that the FDA would find the data obtained from that clinical trial sufficient to support Trevena’s NDA; (e) because the Phase III clinical trial data being derived would not likely be deemed sufficient to support the NDA for Olinvo, the Company would not be able to market Olinvo as soon as it was leading the market to expect, if ever; and (f) as a result of the foregoing, the Company was not on track to achieve the commercial sales revenues from Olinvo as soon as Defendants had led the market to expect during the Class Period, if ever.
Get additional information about the TRVN lawsuit: http://www.kleinstocklaw.com/pslra-1/trevena-inc-loss-submission-form?wire=3
Camping World Holdings, Inc. (NYSE: CWH)
Class Period: March 8, 2017 to August 7, 2018
Lead Plaintiff Deadline: December 18, 2018
The complaint alleges Camping World Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s disclosure controls and controls over financial reporting suffered from a host of material weaknesses; (2) the Company’s historical financial results had been materially misstated; (3) the Gander stores had encountered integration setbacks, adversely impacting the Company’s earnings growth and profit margins; and (4) the Company’s core RV business was experiencing decelerating growth as the Company lagged industry trends and was losing market share to competitors.
Get additional information about the CWH lawsuit: http://www.kleinstocklaw.com/pslra-1/camping-world-holdings-inc-loss-submission-form?wire=3
Honeywell International Inc. (NYSE: HON)
Class Period: February 9, 2018 to October 19, 2018
Lead Plaintiff Deadline: December 31, 2018
The lawsuit alleges that throughout the class period, Honeywell International Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Honeywell’s Bendix Friction Materials ("Bendix") asbestos-related liability was greater than initially reported; (2) the Company maintained improper accounting practices in connection with its Bendix asbestos-related liability; and (3) as a result, Honeywell’s public statements were materially false and misleading at all relevant times. Honeywell previously owned Bendix, which used asbestos in its brake- and clutch-pad products until 2001; the Company sold Bendix in 2014.
On August 23, 2018, Honeywell announced it had "revised its method for reasonably estimating its liability for unasserted Bendix asbestos-related claims by considering the epidemiological projections through 2059 of future incidence of Bendix asbestos-related disease. Using this method, the Company’s Bendix asbestos-related liability is estimated to be $1,693 million as of June 30, 2018. This is $1,083 million higher than the Company’s prior estimation which applied a five-year horizon when estimating the liability for unasserted Bendix asbestos-related claims. The Bendix asbestos-related insurance assets are estimated to be $187 million as of June 30, 2018, which is $65 million higher than the Company’s prior estimate."
Get additional information about the HON lawsuit: http://www.kleinstocklaw.com/pslra-1/honeywell-international-inc-loss-submission-form?wire=3
Dycom Industries, Inc. (NYSE: DY)
Class Period: November 20, 2017 to August 10, 2018
Lead Plaintiff Deadline: December 24, 2018
The lawsuit alleges that Dycom Industries, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Dycom’s large projects were highly dependent on permitting and tactical considerations, (ii) Dycom was facing great uncertainties related to permitting issues; (iii) said uncertainties would expose Dycom to near-term margin pressure and absorption issues, and (iv) as a result of the foregoing, Defendants’ statements about Dycom’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
Get additional information about the DY lawsuit: http://www.kleinstocklaw.com/pslra-1/loss-submission-form-2?wire=3
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com